An Australian company has defended its online promotion of CA125 “ovarian cancer check” tests. The company, i-screen, is marketing the CA125 test direct to consumers for $49, as one of a suite of tests to “track key biomarkers in your blood before they become an issue”. Consumers who buy the test online receive a pathology ...
Company defends online marketing of CA125 ovarian cancer checks
By Tessa Hoffman
10 Oct 2018